Jose Cuervo, the world’s top-selling tequila brand, says it is not a supporter of the additive-free campaign that has swept ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein.

Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...

Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B round. The fresh cash will help Curevo advance Phase 2 trials of amezosvatein ...

Former Chair of GSK’s vaccine business and Chief Scientific Advisor to Operation Warp Speed, Moncef Slaoui, to join Curevo as Board Chair SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Curevo ...

Concurrent with the round, Moncef Slaoui, PhD, will join Curevo as Board Chair. Dr. Slaoui was most recently the Chief Scientific Advisor to Operation Warp Speed during the COVID-19 pandemic ...

Did the government turn a blind eye to a gangster training-camp in Jalisco?

Seattle, USA-based biotech Curevo Vaccine, which is developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the closing of a $110 million Series B round to advance ...